It’s good to be heard – the APO determines section 40 requirements
The Australian Patent Office’s decision in The University of British Columbia APO 15 (20 March 2020) considers how the “raised bar” requirements of support (section 40(3)), enablement (section 40(2)(a)) and...
The Australian Patent Office’s decision in The University of British Columbia APO 15 (20 March 2020) considers how the “raised...
Read More
Coronavirus the global pandemic: a guide to patenting
COVID-19 (short for coronavirus disease 2019) is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more commonly referred to as coronavirus. Coronavirus has dominated world headlines in 2020, leading to nationwide...
COVID-19 (short for coronavirus disease 2019) is caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more commonly referred to...
Read More
COVID-19: mRNA vaccines – a promising approach to vaccine development
The urgent need to develop an effective vaccine to provide individuals and populations worldwide with immunity against the COVID-19 disease caused by the novel coronavirus, SARS-CoV-2, has led several...
The urgent need to develop an effective vaccine to provide individuals and populations worldwide with immunity against the COVID-19...
Read More
Biosimilars in Australia
A ‘biosimilar medicine’ or ‘biosimilar’ is a highly similar, but not identical, version of an original biological medicine (‘reference medicine’) – a medicine comprised of large complex molecules derived...
A ‘biosimilar medicine’ or ‘biosimilar’ is a highly similar, but not identical, version of an original biological medicine (‘reference...
Read More
Conference poster presentations as prior art for the assessment of novelty of a later patent application
Conferences are an important way for scientists and researchers to share and promote their research. They typically include poster presentation sessions where researchers present their findings. Conferences help generate interest in the scientific community...
Conferences are an important way for scientists and researchers to share and promote their research. They typically include poster presentation sessions...
Read More
Diagnostic Methods in Australia
In Sequenom, Inc. v Ariosa Diagnostics, Inc. FCA 1011, the Federal Court confirmed that diagnostic methods are patentable subject-matter in Australia. This will be a satisfying result for...
In Sequenom, Inc. v Ariosa Diagnostics, Inc. FCA 1011, the Federal Court confirmed that diagnostic methods are patentable...
Read More
China Government Releases New Regulation on Human Genetic Resource
On May 28, 2019, China’s State Council releases a new Regulation of Human Genetic Resources (the “Regulation”) which will become effective on July 1. For the life sciences industry and research organizations...
On May 28, 2019, China’s State Council releases a new Regulation of Human Genetic Resources (the “Regulation”) which will become effective on...
Read More
Will the United States Congress Clean-Up the Patent Eligibility Mess?
Steps are currently being taken by the United States congress to address the issue of patent eligible subject matter that has plagued the United States patent system in recent...
Steps are currently being taken by the United States congress to address the issue of patent eligible subject matter...
Read More
The “plausibility” threshold remains low in Australia
The requirement that a patent specification sufficiently enables the subject matter of the claims is particularly relevant to pharmaceutical inventions and can be a hurdle for innovators even if...
The requirement that a patent specification sufficiently enables the subject matter of the claims is particularly relevant to pharmaceutical...
Read More